LUCIDITY phase 3 topline data presented at CTAD for HMTM – the only oral anti-Tau therapy in…
- Tau aggregation inhibitor, HMTM, is an oral drug with a strong safety profile, having no risk of amyloid related imaging abnormalities
- Topline results for the Phase 3 study, LUCIDITY, were shared at the Clinical Trials in…
Weiterlesen...
Weiterlesen...